HCA — HCA Healthcare, Inc.

HCA Healthcare Q2 2026 Earnings Call Summary

1. Key Financial Results and Metrics:

• Earnings Growth: Solid diluted earnings per share (EPS) growth of 11% for the quarter and year-to-date.
• Volume Metrics:
  • Admissions increased by 2.5%, equivalent admissions up 2.7%.
  • Inpatient surgeries down 2.3%, outpatient surgeries down 3.4%.
  • Emergency room visits increased by 3.6%.
• Payer Mix Impact: A significant decline in patients covered by health insurance exchanges (down 15%), with a corresponding rise in uninsured patients (up 15%).
• Adjusted EBITDA: The unfavorable payer mix shift negatively impacted adjusted EBITDA by approximately $400 million in the quarter.
• Revenue Growth: Net revenue per equivalent admission grew by 6.4% due to payment benefits and contracted rate increases.
• Cash Flow: Cash flow from operations was $2.3 billion, a 45% decline from the prior year.

2. Strategic Updates and Business Highlights:

• Capital Investments: HCA plans to invest over $7 billion in capital expenditures over the next three years to enhance capacity and quality of care.
• Resiliency Program: Continued advancement in operational efficiencies and cost management through a financial resiliency program, showing improvements in cost metrics.
• Market Positioning: HCA is maintaining or growing market share in many regions, with ongoing investments in both inpatient and outpatient facilities.

3. Forward Guidance and Outlook:

• Revised Guidance for 2026:
  • Revenue expected between $77 billion and $79.5 billion.
  • Adjusted EBITDA projected between $15.4 billion and $16.1 billion.
  • Net income attributable to HCA expected between $6.3 billion and $6.7 billion.
  • Diluted EPS forecasted between $28.70 and $30.50.
• Long-term Growth Rate: The revised guidance aligns with long-term adjusted EBITDA growth targets of 4% to 6%.

4. Bad News, Challenges, or Points of Concern:

• Payer Mix Shift: The transition of patients from health insurance exchanges to uninsured status has created significant financial pressure, particularly in three divisions that accounted for 50% of the impact.
• Surgery Volume Declines: A notable decrease in elective surgeries attributed to reduced demand and economic pressures affecting patients' ability to afford care.
• Cash Flow Decline: Significant drop in cash flow from operations due to timing differences related to Medicaid supplemental payments.
• Regulatory Risks: Potential impacts from proposed Medicaid work requirements and ongoing uncertainties surrounding health insurance exchange policies.

5. Notable Q&A Insights:

• Exchange Headwinds: Management clarified that the increased estimate for exchange headwinds is primarily due to a higher-than-expected migration of patients to uninsured status (1-for-1), rather than the originally estimated 80-85%.
• Surgery Trends: Inpatient surgeries are stable, driven by emergency cases, while elective surgeries are declining, influenced by economic factors and changes in insurance coverage.
• Market Dynamics: HCA's competitive positioning remains strong, with ongoing investments to expand both inpatient and outpatient services in response to demographic trends supporting growth in key markets.
• Professional Fees: Elevated growth in professional fees, particularly in anesthesia and radiology, continues to be a concern, though stabilization efforts are underway.

Overall, HCA Healthcare's Q2 2026 results reflect a mix of solid earnings growth and operational challenges, particularly related to payer mix and surgery volumes, while maintaining a focus on strategic investments for future growth.